What’s a GLP-1 Drug? Understanding the Role of GLP-1 Agonists in Weight Loss and Diabetes Management

Last reviewed: June 7, 2026

Last updated: June 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

A GLP-1 drug is a receptor agonist — an engineered molecule that binds and activates the glucagon-like peptide-1 receptor, producing glucose-dependent insulin secretion, delayed gastric emptying and reduced appetite. The class now spans two indication families that are frequently confused: type 2 diabetes products such as Ozempic and Mounjaro, and weight-management products such as Wegovy and Zepbound. Knowing which document governs which product is the difference between an informed conversation and a misinformed one.

What Makes It a Drug Rather Than a Hormone

Native GLP-1 is degraded within minutes by dipeptidyl-peptidase 4, which is why it never became a therapy in its own right. The drugs in this class are structurally engineered to survive.

Semaglutide’s peptide backbone is produced by yeast fermentation, modified at position 8 to resist DPP-4 degradation and at position 26 with a hydrophilic spacer and a C18 fatty di-acid that binds albumin. Albumin binding is the main protraction mechanism and yields an elimination half-life of approximately one week, with absolute bioavailability of 89% after subcutaneous administration.

That engineering is what converts a transient postprandial signal into a once-weekly medication with steady-state exposure reached after 4 to 5 weeks of dosing.

The Diabetes Side of the Class

Ozempic injection is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

The Rybelsus and Ozempic tablets label covers oral semaglutide for glycemic control in adults with type 2 diabetes and for reduction of major adverse cardiovascular events in adults with type 2 diabetes at high risk for those events.

Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes. None of these carries a weight-management indication.

The Weight-Management Side of the Class

Wegovy injection is indicated to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight, to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 and older with obesity and in adults with overweight plus at least one weight-related comorbid condition, and for noncirrhotic MASH with moderate to advanced fibrosis under accelerated approval.

Zepbound is indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity or with overweight plus at least one weight-related comorbid condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.

Oral options have expanded here too. Wegovy tablets carry cardiovascular risk reduction and weight reduction indications in adults, and Foundayo (orforglipron), approved April 1 2026, is an oral tablet indicated for chronic weight management.

Single Versus Dual Receptor Agonism

Semaglutide acts at one receptor. Tirzepatide is a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist, engaging a second incretin pathway. That difference has been tested directly.

In SURMOUNT-5, a 72-week open-label phase 3b trial in 751 adults with obesity but without type 2 diabetes, participants received the maximum tolerated dose of tirzepatide (10 mg or 15 mg) or of semaglutide (1.7 mg or 2.4 mg). Least-squares mean weight change at week 72 was −20.2% with tirzepatide and −13.7% with semaglutide, and waist circumference fell −18.4 cm versus −13.0 cm.

The most common adverse events in both arms were gastrointestinal, mostly mild to moderate, occurring primarily during dose escalation. Larger average effect and larger average gastrointestinal burden move together in this class.

Cardiovascular and Renal Effects Are Part of the Story

This class is no longer only about glycemia and weight. Two of Ozempic’s three indications are outcome indications rather than surrogate ones: reduction of major adverse cardiovascular events, and reduction of the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in chronic kidney disease.

On the weight-management side, Wegovy injection carries its own cardiovascular outcome indication in adults with established cardiovascular disease and either obesity or overweight, and Zepbound carries an obstructive sleep apnea indication. These are separate approvals supported by separate trials, not extrapolations from weight change.

The Shared Safety Framework

Every product in the semaglutide and tirzepatide families carries a boxed warning about thyroid C-cell tumors observed in rodents, with human relevance undetermined, and contraindicates use in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Warnings and precautions recur across the labels: acute pancreatitis, acute gallbladder disease, acute kidney injury due to volume depletion, hypoglycemia when combined with insulin or an insulin secretagogue, severe gastrointestinal adverse reactions, hypersensitivity reactions, and pulmonary aspiration during general anesthesia or deep sedation.

Drug interaction language differs by product and is worth reading rather than assuming. The Ozempic injection label says to use with caution with oral medications; the oral semaglutide label directs prescribers to consider increased clinical or laboratory monitoring for oral drugs with a narrow therapeutic index.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

What does GLP-1 agonist actually mean?

An agonist is a molecule that binds a receptor and activates it. A GLP-1 receptor agonist binds the glucagon-like peptide-1 receptor and reproduces the hormone’s effects: glucose-dependent insulin secretion, suppression of glucagon when glucose is elevated, delayed gastric emptying and reduced appetite. Unlike the native hormone, these molecules resist rapid enzymatic degradation.

Which GLP-1 drugs treat diabetes and which treat obesity?

Ozempic injection, Rybelsus and Ozempic tablets, and Mounjaro carry type 2 diabetes indications. Wegovy injection and tablets, Zepbound, and Foundayo (orforglipron) carry weight-management indications, with Wegovy injection also covering cardiovascular risk reduction and noncirrhotic MASH, and Zepbound also covering moderate to severe obstructive sleep apnea in adults with obesity.

Is tirzepatide a GLP-1 drug?

It is a dual agonist. Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the GLP-1 receptor, engaging two incretin pathways rather than one. That is a genuine pharmacological distinction from semaglutide, and in the SURMOUNT-5 head-to-head trial it produced a larger mean weight change over 72 weeks, minus 20.2% versus minus 13.7%.

Do these drugs do anything besides lower weight and glucose?

Yes, and several of those effects are separately approved. Ozempic carries indications for reducing major adverse cardiovascular events and for reducing the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in chronic kidney disease. Wegovy injection carries a cardiovascular outcome indication and a MASH indication, and Zepbound covers obstructive sleep apnea.

What are the main risks of the class?

All these labels carry a boxed warning about rodent thyroid C-cell tumors and contraindicate use with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Labeled warnings include acute pancreatitis, acute gallbladder disease, acute kidney injury from volume depletion, hypoglycemia with insulin or secretagogues, and pulmonary aspiration under anesthesia.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.